HIV Infections Clinical Trial
Official title:
An Enhanced Adherence Support Programme for HAART
In southern Africa, TB is the most common first AIDS-defining condition. Initiating
Antiretroviral therapy (ART) in HIV positive TB patients will lead to the inclusion of the
majority of HIV/AIDS patients currently fulfilling the criteria for therapy. Establishing an
effective intervention to increase treatment adherence in this group is essential for the
successful roll out of ART in the region. This proposed randomized controlled study aims to
compare the effectiveness of two adherence support programmes (ASP) for use in patients with
HIV-related TB in the context of CAPRISA AIDS Treatment (CAT)programme in KwaZulu-Natal,
South Africa; the enhanced adherence support programme (E-ASP) or the standard adherence
support programme (S-ASP).
S-ASP consists of three counselor presented, group education sessions. E-ASP is an extension
of S-ASP and is based on the Information-Motivation-Behavioral Skills (IMB) Model of
Adherence to Antiretroviral Therapy, a theoretical model initially developed to reduce HIV
risk behavior. The E-ASP will consist of several interconnected components: 1) development
and maintenance of an educational and supportive milieu at the CDC Clinic, 2) provision of
five structured educational, support and behavioral skills building sessions, and (3) three
weekly ART planning sessions.
Enhanced Adherence Support (E-ASP)
All patients will receive sessions one and two of the Standard ASP. Following randomization,
the intervention (experimental) arm patients receive the E-ASP described below and the
standard of care (control) arm patients receive session three of the S-ASP.
Two health educators are employed and trained to administer E-ASP. The goal of the E-ASP is
to identify and address patient deficits in information, motivation, and behavioural skills
that inhibit consistent and correct self-administration of ARV medications, including those
skills required to adhere to the clinic visit schedule. By using specific motivational
techniques (Motivational Interviewing) and structured one-on-one sessions, the health
educator empower patients to pre-empt situations that have been shown to lead to
non-adherence and make plans for situations in which they are less likely to adhere.
Components of the E-ASP
The E-ASP augments S-ASP and consistS of several interconnected components: 1) development
and maintenance of an educational and supportive milieu at the CDC Clinic, 2) provision of
five structured education, support and behavioural skills building sessions, and (3) three
weekly ART planning sessions.
Development and Maintenance of an Educational and Supportive Milieu
A separate room is available for exclusive use of the E-ASP. This room has educational
materials available at all times, and is a comfortable area for patients to relax and
socialize with one another during the course of their time at the CDC clinic.
Provision by Study Health Educator of 5 Structured Education, Support, and Behavioural
Skills Sessions
The educational, support, and behavioural skills building sessions consist of five,
one-on-one interactive sessions that will be conducted by the health educator. The sessions
take place at five important times during patients' early ART:
1. On the day of commencement of ART - "Preparing to take ART medications"
2. 2 weeks after starting ART - "Adjusting to taking ART medications"
3. 2 months after starting ART - "Feeling good and staying healthy taking ART medications"
4. 3 months after starting ART - "Planning for ongoing HIV care and daily ART medications"
5. 6 months after starting ART - "Preparation for lifelong HIV care and daily ART
medications"
The content matter (key educational, support and skills points/messages) for the sessions is
conveyed by the study health educator using specially designed story board flip charts, put
into table-standing easel display books; the front side faces the patient and the backside
faces the health educator. Posters including all pertinent images and messages will be put
onto the walls for ease of summarizing the information, and for providing an overview of
important messages. All messages will also be conveyed in pictorial form to ensure that
literacy levels of the cohort do not negatively affect understanding.
The other important educational, motivation and skills building tool available is a
double-sided Adherence Problem Solving Pocket Card. This tool lists commonly occurring
medication adherence problems on the front side and practical solutions/strategies on the
back.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |